The present invention provides improved processes for the preparation of Bortezomib, tert-butyl[1-({(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate of formula (IV) and N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6- methano-1,3,2-benzodioxaborol-2-yl]butyl} phenylalanine of formula (V). Compound (IV) is prepared by coupling (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethyl- hexah...

A pharmaceutical composition comprises cinacalcet or its salt, solvate, derivative, hydrate, anhydrate, enantiomer, polymorph, prodrug or complex and at least one pharmaceutically acceptable polymer. A process for preparing a pharmaceutical composition comprising cinacalcet or its salt, solvate, derivative, hydrate, anhydrate, enantiomer, polymorph, prodrug or complex and at least one pharmaceutically acceptable polymer, comprises hot melt extrusion of the cinacalcet polymer blend to form extrud...

There is provided a process for the preparation of sitagliptin or a pharmaceutically acceptable salt thereof, and a process for the preparation of intermediate compounds useful in the preparation of sitagliptin. In particular, there is provided a process comprising condensing 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl) butyric acid of formula (II) with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a] pyrazine of formula (III) or a salt thereof in presence of a catalyst to o...

A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.

A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament.

A pharmaceutical composition comprising efavirenz wherein the efavirenz is in the form of nanoparticles is disclosed.

The present invention relates to a pharmaceutical composition comprising voriconazole and an aqueous, non-aqueous, or oily vehicle, or a mixture thereof, and optionally one or more pharmaceutically acceptable excipients

The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration), to a process for preparing such a composition and to the use of such a composition for the treatment treatment and/or prevention of respiratory, inflammatory or obstructive airway disease.